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Standard versus Dose-Intensified Chemotherapy with
Sequential Reinfusion of Hematopoietic Progenitor Cells in
Small Cell Lung Cancer Patients with Favorable Prognosis
Erika Buchholz, MD,* Christian Manegold, MD,* Lothar Pilz,†
Nick Thatcher, MD, BChir, PhD,‡ and Peter Drings, MD§
Purpose: The combination of ifosfamide, carboplatin, and etoposide
(ICE) is highly effective in treating small cell lung cancer (SCLC).
Myelosuppression resulting in leukopenia and thrombocytopenia is
the dose-limiting toxicity.
Patients and Methods: This phase 3 study assessed 2-year survival
improvement with dose intensification of ICE chemotherapy (ICT)
in patients with good-prognosis SCLC. Patients received up to six
cycles of ICT with filgrastim-supported sequential reinfusion of
peripheral blood progenitor cells every 14 days, or standard ICE
(SCT) every 28 days.
Results: Eighty-three patients were randomized to ICT (n  42) or
SCT (n 41). Median survival was significantly improved with ICT
(30.3 mo) versus SCT (18.5 mo; p  0.001); 2-year survival was
55% for ICT and 39% for SCT (p  0.151). Time to progression
(TTP) was significantly improved, with 15 months for ICT versus
11.1 months for SCT (p  0.0001). Overall response rates were 100
and 88% for ICT and SCT, respectively (p  0.0258). SCT was
associated with significantly less grade 3 and 4 leukopenia at day 8
(p  0.0001), less thrombocytopenia at day 14 (p  0.0001), and
more favorable platelet nadir (p 0.0001). The need for platelet and
red blood cell transfusions significantly increased in the ICT group
(p  0.0001). Nonhematologic adverse events in both groups were
comparable and mostly grade 1 or 2.
Conclusion: Patients receiving ICT with filgrastim achieved signif-
icant increases in median survival and TTP despite an increased
need for transfusions.
KeyWords: Small cell lung cancer, Hematopoietic progenitor cells,
Filgrastim, ICE, Chemotherapy.
(J Thorac Oncol. 2007;2: 51–58)
Standard combination chemotherapies for the treatment ofsmall cell lung cancer (SCLC) achieve response rates in
up to 80% of patients, with a higher rate of complete response
for patients with limited disease and better prognosis.1–3
Combination regimens containing highly active ifosfamide,
carboplatin or cisplatin, and etoposide (ICE), often in com-
bination with vincristine (V-ICE), are common treatment
options for SCLC.2,4–7 Despite therapeutic improvements for
patients with limited disease, overall median 5-year survival
rates have been reported as only approximately 25%.8,9
Therefore, novel treatments and strategies are needed to
improve response and survival for patients with SCLC. Var-
ious investigated strategies are high-dose versus standard
chemotherapy, prolonged initial treatment, or maintenance
therapy, which may provide some survival benefits but often
with increased toxicity.10–12
This study was designed to compare the feasibility and
safety of dose-intensified ICE (ICT) with filgrastim support
and peripheral blood progenitor cell (PBPC) reinfusion with
standard-dose ICE (SCT) and to determine overall and 2-year
survival for both regimens.
PATIENTS AND METHODS
Patient Characteristics
Eligible patients were no older than 70 years and had
newly diagnosed and previously untreated histologically or
cytologically proven SCLC. Patients needed an Eastern Co-
operative Oncology Group score of 0 or 1, a prognostic
Manchester score of 0 or 1,13 a white blood cell count (WBC)
of at least 3  109/liter, a platelet count of at least 100 
109/liter, and normal cardiac, hepatic, and renal function.
Before the study, all patients underwent disease staging that
included a chest radiograph, liver and brain scan, bone
marrow aspiration, and bone marrow biopsy (if the patient
agreed). Patients with brain metastases or bone marrow
metastases were excluded. Patients with prior treatment with
cytokines or interferons and steroid dependency were not
excluded. All patients provided signed informed consent.
This study was approved by the local ethics committee and
conducted according to the Declaration of Helsinki and the
International Conference on Harmonisation.
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Study Design and Treatment
This single-center study was initially planned as a
phase 2 pilot study in 1996 with a sample size of 40 patients.
After an interim analysis in 1999, the study design was
amended to a phase 3 study to possibly detect statistically
significant difference in 2-year survival observed at the in-
terim analysis. The amendment was approved by the Univer-
sity of Heidelberg ethics committee. At that time it was
believed that 2-year survival rate was about 10% in standard
therapy and should be 25% or higher in intensified therapy.
Therefore, with a power of 80% and a significance level of
  0.05, our planning indicated that 58 eligible patients per
treatment arm should be recruited. Assuming a loss to fol-
low-up of 20%, 64 patients in each treatment arm were
recruited. Five interim analyses were planned, and the study
was to be stopped if the 2-year survival time of the intensified
therapy was significantly higher (p  0.01) using the one-
sided log-rank test. The third interim analysis of 70 patients
(35 patients in each arm) showed a 22% increase in the 2-year
survival rate for patients receiving ICT. This finding was
statistically significant (p  0.003), and patient recruitment
was halted.
Patients were randomized (1:1) to receive up to six
cycles of either ICT with filgrastim support and PBPC rein-
fusion every 2 weeks, or SCT every 4 weeks (Figure 1). The
study design was based on a 1995 study by Pettengell et al.14
Patient randomization was not stratified and was conducted as
an intramural randomization provided by an external random-
ization list conducted by WiSP (Wissenschaftlicher Service
Pharma, GmbH, Dr. Axel Hinke, Langenfeld, Germany). No
dose reduction was allowed. Chemotherapy was administered
if the WBC was at least 3  109/liter, the platelet count was
at least 30 109/liter, and creatinine clearance was at least 50
ml/min; chemotherapy could be delayed for up to 1 week
without PBPC reinfusion. Patients could receive transfusions
to maintain a hemoglobin level of at least 8 g/dl and a platelet
count of at least 20 109/liter. Patients in the ICT group who
needed a 2-week treatment delay reverted to SCT for the
remaining cycles. Filgrastim was administered to patients
receiving ICT on days 4 to 13 of each cycle (the study
protocol required administration of 300 g/day for patients
who weighed less than 70 kg and 5 g/kg per day for patients
who weighed at least 70 kg; in practice, patients who weighed
less than 65 kg received 300 g, and patients who weighed
more than 65 kg received 480 g). Venesection was used to
collect 750 ml of whole blood into standard blood donor
bags. The collection and storage of blood was done by the
Institute for Immunology of the Ruprecht-Karls University of
Heidelberg. Whole blood was stored at 4°C and reinfused as
a normal blood transfusion for a 1-hour period within 56
hours of harvest and at least 24 hours after the next ICT cycle.
The primary endpoint of this study was the 2-year
survival rate for SCT compared with that of ICT. Secondary
efficacy endpoints included the median overall and 1-year
survival rate and time to progression (TTP) in both treatment
arms. Response was assessed according to prespecified cri-
teria.15 Briefly, complete response was defined as the disap-
pearance of all clinical evidence of tumor at two assessments
at least 4 weeks apart; partial response was a decrease of at
least 50% in the sum of products of biperpendicular diameters
without new or enlarged lesions at two assessments at least 4
weeks apart; progressive disease was defined as an increase
of at least 25% in the sum of products of biperpendicular
diameters and the appearance of a new lesion.
Secondary safety endpoints included grade 3 and 4
hematologic adverse events (hemoglobin, WBC, and platelet
count on days 8 and 14 and at nadir), including transfusion
requirements. Nonhematologic adverse events were assessed
according to National Cancer Institute Common Toxicity
Criteria, version 2.0.16 Response and hematologic and renal
FIGURE 1. Ifosfamide, carboplatin, and etoposide (ICE) chemotherapy schedules. The upper panel shows the 28-day
standard ICE (SCT) schedule, and the lower panel shows the dose-intensified ICE (ICT) schedule. In the ICT group, filgrastim
was given on days 4 to 14, and hematopoietic progenitor cells in 750 ml of whole blood were collected on day 1 of cycle 2,
with reinfusion on day 3 of cycles 2 to 6.
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parameters were assessed before each cycle, and transfusion
requirements and adverse events were assessed at each visit.
Follow-up assessments, including type of second-line therapy
where available, were performed every 6 months until death.
Statistics
Survival probabilities and TTP were calculated accord-
ing to the Kaplan–Meier method.17 Differences in the distri-
bution of continuous and categorical variables were assessed
using the Wilcoxon, Fisher’s exact, chi-square, and log-rank
tests. Median exposures to each treatment were calculated as
described above and summarized as box plots.15
RESULTS
Patient Characteristics
Of the 83 patients enrolled from October 1996 to June
2002 at the Thoraxklinik, Heidelberg, Germany, 42 received
ICT and 41 received SCT. Baseline and disease characteris-
tics of the two groups were generally balanced (Table 1). The
majority of patients were male (75%), with a median age of
54.2 years (higher for the SCT group). Only three ICT
patients and one SCT patient had extensive disease. A total of
33 ICT patients (79%) and 26 SCT patients (63%) completed
this study; six ICT patients (14%) and nine SCT patients
(22%) discontinued because of adverse reactions. Four pa-
tients in the SCT group discontinued because of progressive
disease, and one patient in each group withdrew consent. Ten
patients were switched from ICT to SCT because of hema-
tologic toxicity (two patients), patient request (three patients),
two treatment delays (two patients), hepatitis C infection (one
patient), or other reasons that were not study drug related
(two patients). No patients died during the study.
Treatment Exposure and Dose Intensity
The study protocol did not allow any dose reductions.
The median treatment durations were 2.5 and 4.7 months for
ICT and SCT, respectively (Table 2). A total of 446 cycles
were administered, with a median of six cycles in both
groups. Significantly more patient-cycles were administered
in the ICT group than in the SCT group (p  0.0038; Table
2), and more ICT patients than SCT patients received all six
cycles (79 versus 63%). The median dose received in milli-
grams per meter squared of body surface area per week of
ifosfamide was 2484 (range, 475–2761) in the ICT group and
1250 (range, 493–2917) in the SCT group; for carboplatin it
was 148 (range, 29–162) for ICT and 75 (range, 30–175) for
SCT, and for etoposide it was 178 (range, 34–229) for ICT
and 90 (range, 35–210) for SCT (Figure 2). The ratio of
weekly median doses of ICE in ICT compared with SCT were
1.99, 1.97, and 1.98, respectively, and the overall ratio of
administered doses (mean of the ratios) was 1.98 for all
drugs. Seventeen (6.7%) and 35 (14.2%) cycles were missed
in the ICT and SCT groups, respectively. All patients in the
ICT group and nine (22%) in the SCT group received filgras-
tim for a median of 10 and 5.5 days, respectively. More
treatment delays were reported for the ICT compared with the
SCT group (51 versus 15). The majority (82%) of treatment
delays for ICT patients were attributable to hematologic
toxicities, with a median duration of 3 days. Nonhematologic
delays totaled a median of 2 days for ICT and 5 days for SCT.
Because it was the standard in 1996, patients achieving
at least a partial response at the end of chemotherapy treat-
ment were offered thoracic radiation as consolidation treat-
ment and prophylactic cranial radiation, if indicated. The
numbers of patients receiving radiation therapy were similar
in both treatment arms: brain (25 [60%] ICT and 23 [56%]
SCT), chest (40 [95%] ICT and 35 [85%] SCT), and brain
and chest in the same patient (25 [57%] ICT and 22 [54%]
SCT).
Survival and Response
The median length of follow-up for the ICT group
was 23.9 (range, 0.4 –87.0) months versus 13.7 (range,
TABLE 1. Baseline Characteristics
Characteristic
ICT SCT
(n  42) (n  41)
Median age, years (range) 50.9 (28–64) 56.9 (36–69)
Male sex, n (%) 30 (71) 32 (78)
Mean weight, kg (SD) 75.3 (12.5) 81.6 (13.1)
Disease stage, n (%)
Limited 39 (93) 40 (98)
Extensive 3 (7) 1 (2)
ECOG performance status, n (%)
0 1 (2) 3 (7)
1 41 (98) 38 (93)
Manchester score, n (%)
0 21 (50) 21 (51)
1 21 (50) 20 (49)
Serum sodium level  normal, n (%) 6 (14) 6 (15)
Serum lactate dehydrogenase
200, n (%)
20 (48) 20 (49)
Alkaline phosphatase, grade 1, n (%) 0 1 (2)
Median time to treatment from SCLC
diagnosis, days (range)
9 (0–22) 10 (1–25)
ECOG, Eastern Cooperative Oncology Group; SCLC, small cell lung cancer; SD,
standard deviation.
TABLE 2. Exposure
ICT, n (%) SCT, n (%)
Number of patient-cycles 235 211
Median treatment duration, mo 2.5 4.7
Reason for delay, n (median days)
Hematologic toxicity 42 (3) 6 (7.5)
Not study related 9 (2) 9 (5)
Median number of cycles delivered 6 6
6, n (%) 33 (79) 26 (63)
5, n (%) 1 (2) 6 (15)
4, n (%) 8 (17) 2 (5)
3, n (%) 0 4 (10)
2, n (%) 0 2 (5)
1, n (%) 0 1 (1)
ICT, dose-intensified ICE (ifosfamide, carboplatin, and etoposide); SCT, standard
ICE.
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2.2–53.0) months for SCT. At the last follow-up, 26 of the
62 (62%) patients who had died were in the ICT group, and
36 (88%) were in the SCT group, representing a signifi-
cantly improved survival for ICT (p  0.0107). The
median overall survival was statistically significantly pro-
longed for ICT compared with SCT (30.3 versus 18.5
months; p  0.001) (Figure 3). The 2-year survival rate of
55% (23 patients) for ICT was numerically but not signif-
icantly higher compared with the 2-year survival rate of
39% (16 patients) for SCT (p  0.151). The 1-year
survival rate for ICT was slightly increased compared with
that for SCT (81 versus 78%).
A total of 61 patients had experienced disease pro-
gression at the last follow-up (27 for ICT and 34 for SCT).
The median TTP was significantly prolonged in favor of
ICT (p  0.0001), with 15.0 (range, 12.7–31.9) months for
ICT and 11.1 (range, 9.1–11.9) months for SCT (Figure 4).
In the follow-up period, there were statistically signifi-
cantly fewer ICT patients showing progressive disease
compared with SCT-treated patients (p  0.0197, Fisher’s
exact test). For ICT, 16 of 27 patients showed local
progression, and 14 of 27 had distal progression, with three
of 27 patients having both local and distal progression. In
the SCT group, 22 of 34 patients showed local and 18 of 34
had distal progression, with six of 34 demonstrating both
local and distal progression. There was no statistically
significant difference between local (p  0.21) and distal
progressions (p  0.62) within treatment arms.
FIGURE 2. Patient dose intensity in milli-
grams per meter squared per week for the
ICT and SCT groups. Patients in both
groups received a weekly dose of ifosfamide
(A), carboplatin (B), and etoposide (B). ICT,
dose-intensified ICE; SCT, standard ICE.
FIGURE 3. Median overall Kaplan–Meier survival curves for patients receiving ICT (censored  16) and SCT (censored  5).
Median overall survival was statistically significantly improved for patients receiving ICT (p  0.001). ICT, dose-intensified ICE
(ifosfamide, carboplatin, and etoposide); SCT, standard ICE.
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All patients receiving ICT achieved a partial or com-
plete response, and the overall response rate was higher
(100%) than that for SCT (88%; p 0.0258) (Table 3). Three
patients in the SCT group experienced stable disease, and
four had progressive disease while receiving study treatment.
At the last follow-up, statistically fewer ICT patients com-
pared with SCT patients (20 versus 35) had received second-
line treatment (p  0.0004, Fisher’s exact test). Second-line
treatments for progressive disease included radiotherapy of
the chest received by no ICT patients and six SCT patients
(p  0.0119), radiotherapy of the brain received by five ICT
patients and five SCT patients (p  0.05), and all other
antitumor therapies received by 18 ICT patients and 32 SCT
patients (p  0.0016). The most common therapies were
radiation (11 versus 26%), ICE reexposition (14 versus 11%),
and doxorubicin, cyclophosphamide, and vincristine (11 ver-
sus 14%).
Toxicity and Supportive Care
All 446 administered cycles were analyzed for grade 3
and 4 myelotoxicity on days 8 and 14 and for hematologic
nadirs in each cycle. There was no significant difference in
the occurrence of febrile leucopenia; the incidence was 15
(36%) and 15 (37%) for patients and 23 (10%) and 16 (8%)
for cycles in the ICT and SCT arms, respectively. SCT was
associated with a lower incidence of grade 3 and 4 hemoglo-
bin nadir (15.9 versus 20.4%; p 0.00605) and platelet nadir
(46.4 versus 73.2%; p  0.0001) compared with ICT,
whereas the WBC nadirs were similar in both groups.
Because of the increased myelotoxicity with ICT, sig-
nificantly more patients receiving ICT required platelet and
red blood cell (RBC) transfusion packs per cycle than did
those on SCT. Significantly more platelet and RBC transfu-
sion packs were needed in the ICT group (p  0.0001; Table
4). The median patient transfusion requirement was 10 packs
of platelets and nine packs of RBCs for patients receiving
FIGURE 4. Median time-to-progression Kaplan–Meier curves for patients receiving ICT (censored  14) and SCT (censored  2).
Median time to progression was statistically significantly improved for patients receiving ICT (p  0.0001). ICT, dose-intensified ICE
(ifosfamide, carboplatin, and etoposide); SCT, standard ICE.
TABLE 3. Treatment Response
ICT n (%) SCT n (%)
Overall response 42 (100) 36 (88)
Complete response 22 (52) 15 (37)
Partial response 20 (48) 21 (51)
Stable disease 0 3 (7)
Progressive disease 0 2 (5)
ICT, dose-intensified ICE (ifosfamide, carboplatin, and etoposide); SCT, standard ICE.
TABLE 4. Incidence of Transfusions
ICT SCT
n  42 n  41
Platelet or RBC transfusion
Patients receiving transfusion, n (%) 40 (95) 24 (59)
Patient-cycles with transfusion, n/N (%) 129/235 (55) 58/211 (27)
Platelet transfusion only
Patients receiving transfusion 7 (17) 4 (10)
Platelet transfusion packs, n 387 327
RBC transfusion only
Patients receiving transfusion 11 (26) 8 (20)
RBC transfusion packs, n 371 166
ICT, dose-intensified ICE (ifosfamide, carboplatin, and etoposide); SCT, standard
ICE; RBC, red blood cell.
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ICT compared with 12 packs of platelets and eight packs of
RBCs for those receiving SCT.
The incidences of grade 1 and 2 nonhematologic ad-
verse events and fever for the two groups were similar. There
were no grade 3 or 4 toxicities in this study, with the
exception of one grade 3 pulmonary adverse event reported in
the SCT group. Differences in the incidence of certain ad-
verse events were observed; fewer grade 1 and 2 pulmonary
(p 0.001) and cardiac (p 0.0019) toxicities were reported
for ICT, whereas fewer episodes of grade 1 or 2 nausea (p 
0.0209) and vomiting (p 0.0160) were reported for the SCT
group. Creatinine data were normal for all analyzed cycles in
both groups, with the exception of one grade 1 toxicity in a
patient receiving SCT. Other toxicities included those previ-
ously reported for ICE-based combination regimens.
DISCUSSION
SCLC is known to be highly sensitive to initial therapy,
but relapsed SCLC is often resistant to chemotherapy and
radiotherapy, emphasizing the importance of complete initial
treatment response to minimize the risk of resistant relapse. A
promising strategy for increasing initial complete response
rates and survival has been the dose intensification of cyto-
toxic regimens by either increasing the individual dose size or
decreasing dose intervals.18–23 Aggressive, more ICT for
patients with SCLC led to higher response rates, prolonged
overall survival, and increased 2-year survival rates up to 30
to 33% compared with studies of standard regimens.24–27
The introduction of autologous PBPC reinfusion in
whole blood or after leukapheresis preparation with filgrastim
support allowed for the safe delivery of significantly dose-
intensified chemotherapy.28–31 Multiple studies suggested
that single or sequential reinfusion of PBPCs was feasible,
allowing for the dose intensification of ICE by a factor of
1.80.32–41 These studies reported significant improvements
for patients with limited-disease SCLC but showed less
benefit for patients with extensive-disease SCLC.
Our randomized phase 3 study demonstrated that the
dose intensity of six cycles of ICE therapy in patients with
limited-disease SCLC can be significantly increased by short-
ening the therapy from 4 to 2 weeks when proactively treated
with filgrastim and reinfusion of autologous PBPC in whole
blood at each cycle.
The regimen using six cycles of ICT with repeated
hematopoietic progenitor cell support was previously re-
ported to be safe and effective in a phase 2 study of patients
with limited-disease SCLC.39 Therefore, our study not only
confirmed the promising results reported in that phase 2 study
but, for the first time, reported significantly increased sur-
vival. All patients who received ICT achieved a complete or
partial response, and the ICT group had a statistically signif-
icantly prolonged median overall survival, a statistically sig-
nificantly prolonged TTP, and a better 2-year survival rate
compared with SCT.
In contrast, the larger, similarly designed study by
Lorigan et al.42 in the same patient population reported
different results. In the Lorigan et al.42 study, the delivered
median dose intensity was 99% (interquartile range: 96–
100%) for the standard arm and 182% (interquartile range:
163–196%) for the dose-dense arm. Median overall survival
was 13.9 months (95% confidence interval [CI]: 12.9–15.8
mo) in the standard arm and 14.4 months (95% CI: 12.7–16.0
mo) in the dose-dense arm, and 2-year survival was 22%
(95% CI: 16–29%) and 19% (95% CI: 14–27%), respective-
ly.42 In contrast, our study patients received a higher median
number of chemotherapeutic cycles (six cycles), and a higher
chemotherapy density (1.98) was achieved. Our study could
be criticized for having been performed in a single institution
with a small number of patients. However, our positive
results find at least some support by the larger study. Of note,
in the Lorigan et al.42 study, there was a trend toward
improved outcomes among patients with limited disease in
the dose-dense arm.
Two studies demonstrated that the dose intensity of
ICE-based regimens could be safely increased 1.26- and
1.34-fold using V-ICE with growth factor support in patients
with SCLC.41,43 Importantly, only the addition of repeated
progenitor cell support allowed for increased dose intensifi-
cation by a factor of 1.80,39 which is similar to the mean of
relative doses of 1.98 for ICT versus SCT achieved in our
study. This intensity was not reached in other trials. Overall,
despite the increased myelotoxicity, more ICT than SCT
cycles were administered. However, an increased incidence
of treatment delays, mostly attributable to hematologic
events, was observed with ICT compared with SCT.
As demonstrated in our study for ICT, only the con-
current use of hematopoietic growth factors with reinfusion
of autologous hematopoietic progenitor cells allowed for
more significant increases in dose intensity, which translated
into increased response, prolonged time to relapse, and sig-
nificantly increased survival.32–40
Dose intensification is an attractive option for increas-
ing the efficacy of treatments for SCLC. Earlier studies using
the ICE regimen reported promising results, but their designs
provided only limited information about actual survival ben-
efit.24–27 These earlier studies compared the efficacy and
safety of ICE-based regimens in patients with limited and
extensive disease or ICT with alternative regimens, or they
used historic controls. Dose intensification with hematopoi-
etic growth factor but without hematopoietic progenitor cell
support has demonstrated significant median survival benefits
for patients with limited disease.19,27,43
ICT as used with filgrastim and hematopoietic progen-
itor cells was safe for patients with limited-disease SCLC. In
our study, hematologic toxicities for both groups were gen-
erally low but were statistically different for the hemoglobin
nadir (p  0.006) and the platelet nadir (p  0.0001), both in
favor of SCT. Therefore, contrary to the experience in the
phase 2 study, our patients receiving ICT had an increased
need for transfusions, which was also significant for RBCs as
for platelets.39 Most of the nonhematopoietic toxicities in the
two groups were similar, and there was no difference in the
incidence of or reasons for discontinuation. Importantly, no
toxicity-related deaths were reported in our study, compared
with previously studied dose-intensified V-ICE (six chemo-
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therapy-related deaths in the granulocyte colony-stimulating
factor arm).43 In addition, dose intensification of ICE did not
affect the choice of second-line therapy.
Summary
In conclusion, our data support the findings of others
that dose intensity matters and that, in contrast to Lorigan
et al.42, dose intensification with hematopoietic growth fac-
tors may provide survival benefit for patients with limited-
disease SCLC.
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